vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $9.4M, roughly 2.0× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs 65.7%, a 1868.2% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 10.1%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 9.7%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
BYFC vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $18.6M |
| Net Profit | $1.0M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | 1934.0% | 65.7% |
| Revenue YoY | 10.1% | 1808.5% |
| Net Profit YoY | -21.8% | 376.5% |
| EPS (diluted) | $0.02 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $18.6M | ||
| Q3 25 | $9.0M | $334.0K | ||
| Q2 25 | $8.1M | $1.4M | ||
| Q1 25 | $8.3M | $257.0K | ||
| Q4 24 | $8.6M | $977.0K | ||
| Q3 24 | $8.7M | $660.0K | ||
| Q2 24 | $8.2M | $736.0K | ||
| Q1 24 | $7.8M | $1.4M |
| Q4 25 | $1.0M | $12.3M | ||
| Q3 25 | $-23.9M | $-8.6M | ||
| Q2 25 | $752.0K | $-6.9M | ||
| Q1 25 | $-2.7M | $-5.4M | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $516.0K | $-2.8M | ||
| Q2 24 | $256.0K | $-14.5M | ||
| Q1 24 | $-154.0K | $411.0K |
| Q4 25 | — | 56.3% | ||
| Q3 25 | -256.2% | -2516.5% | ||
| Q2 25 | 12.8% | -701.0% | ||
| Q1 25 | -45.3% | -3350.2% | ||
| Q4 24 | 21.7% | — | ||
| Q3 24 | 8.5% | -1563.6% | ||
| Q2 24 | 4.8% | -1255.0% | ||
| Q1 24 | -2.9% | -692.5% |
| Q4 25 | 1934.0% | 65.7% | ||
| Q3 25 | -264.2% | -2572.2% | ||
| Q2 25 | 9.3% | -504.8% | ||
| Q1 25 | -32.3% | -2097.7% | ||
| Q4 24 | 15.3% | — | ||
| Q3 24 | 5.9% | -425.5% | ||
| Q2 24 | 3.1% | -1964.4% | ||
| Q1 24 | -2.0% | 29.9% |
| Q4 25 | $0.02 | $0.25 | ||
| Q3 25 | $-2.86 | $-0.17 | ||
| Q2 25 | $0.00 | $-0.14 | ||
| Q1 25 | $-0.39 | $-0.11 | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $-0.03 | $-0.06 | ||
| Q2 24 | $0.02 | $-0.30 | ||
| Q1 24 | $-0.02 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $49.4M |
| Total Assets | $1.3B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $40.0M | ||
| Q3 25 | $19.7M | $37.9M | ||
| Q2 25 | $29.5M | $44.8M | ||
| Q1 25 | $15.8M | $40.6M | ||
| Q4 24 | $61.4M | $59.3M | ||
| Q3 24 | $97.1M | $68.8M | ||
| Q2 24 | $89.8M | $73.0M | ||
| Q1 24 | $67.1M | $80.2M |
| Q4 25 | $262.8M | $49.4M | ||
| Q3 25 | $261.7M | $36.4M | ||
| Q2 25 | $284.7M | $44.5M | ||
| Q1 25 | $283.6M | $50.5M | ||
| Q4 24 | $285.0M | $55.1M | ||
| Q3 24 | $286.2M | $58.5M | ||
| Q2 24 | $282.1M | $60.4M | ||
| Q1 24 | $281.1M | $74.1M |
| Q4 25 | $1.3B | $59.0M | ||
| Q3 25 | $1.3B | $51.1M | ||
| Q2 25 | $1.2B | $60.7M | ||
| Q1 25 | $1.3B | $67.9M | ||
| Q4 24 | $1.3B | $90.6M | ||
| Q3 24 | $1.4B | $99.0M | ||
| Q2 24 | $1.4B | $107.8M | ||
| Q1 24 | $1.4B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $18.4M |
| Free Cash FlowOCF − Capex | $-13.0K | — |
| FCF MarginFCF / Revenue | -0.1% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 0.22× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $18.4M | ||
| Q3 25 | $3.8M | $-8.7M | ||
| Q2 25 | $3.0M | $-7.5M | ||
| Q1 25 | $-4.3M | $-7.5M | ||
| Q4 24 | $1.4M | $-24.0M | ||
| Q3 24 | $6.1M | $765.0K | ||
| Q2 24 | $9.8M | $-10.9M | ||
| Q1 24 | $-11.7M | $-4.0M |
| Q4 25 | $-13.0K | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $-4.4M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $9.7M | — | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | -0.1% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 37.0% | — | ||
| Q1 25 | -52.4% | — | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 69.6% | — | ||
| Q2 24 | 118.9% | — | ||
| Q1 24 | -149.7% | — |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 0.22× | 1.50× | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYFC
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
